United Kingdom Archives

News and Trends 11 May 2015

PhoreMost awarded €1.96M to target the “undruggable” Cancer Genes

Cambridge-based PhoreMost has been selected to receive a funding award of €1.96M (£1.4 million) from the UK’s innovation agency, Innovate UK, to develop its lead oncology programme targeting mutant KRAS cancers. The British company that aims to provide low-priced and more diversed therapeutics, has developed ‘Site-Seeker’, a next-generation phenotypic screening platform based on PhoreMost’s Protein […]

May 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 10 May 2015

Succesful Phase III for Indivior’s Schizophrenia treatment

Indivior obtained top-line results from its phase III clinical trial of RBP-7000, a candidate treatment for schizophrenia. Based on these successful outcomes, the company expects to submit a New Drug Application to the U.S. FDA for potential approval in 2017. Schizophrenia is a chronic, severe and disabling brain disorder that affects an estimated 26 million […]

May 10, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 8 May 2015

GSK sparks off the Gene Therapy resurgence

GlaxoSmithKline has become the first big pharma company to file a gene therapy approval case to the European Medicines Agency (EMA). The therapy, developed in collaboration with San Raffaele Hospital and the Telethon Foundation in Italy, is designed to cure a disease called adenosine deaminase (ADA) deficiency, which causes severe combined immunodeficiency syndrome, lead to serious infections and, ultimately, death. ADA […]

May 8, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 6 May 2015

Kymab secures €79.8 Million to develop its Antibody-Generating technology

British Kymab raised an additional €44.4M to its already very successful Series B financing. The cash was courtesy of Woodford Patient Capital Trust and Malin Corporation, which joined the Wellcome Trust and the Bill&Melinda Gates Foundation, the previous investors. The British biotech, a monoclonal antibody biopharmaceutical company, successfully raised an additional €44.4M to complete a […]

May 6, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 5 May 2015

Natural Killer therapies for Cancer: a Fast-Evolving field

Natural killers are an emerging approach to fight inflammatory diseases and cancer. These immune actors, that specifically regulate the activity of the immune system, are attracting the attention of several small startups and more than a few big Pharmas. The immune system includes a set of body defenses, that fight foreign forms. But external bodies aren’t […]

May 5, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 4 May 2015

Sygnis on the way to conquer the UK Life Sciences market

Sygnis signed a distribution agreement with Cambridge Bioscience for the commercialization of its proprietary product portfolio in the UK and Ireland. This is a significant expansion of product roll-out into one of the most important life science markets in Europe. Under the terms and conditions of the agreement, Cambridge Bioscience will promote, market, sell and […]

May 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 25 Apr 2015

Desktop Genetics launches a new Gene Editing Platform

Desktop Genetics has just launched the DeskGen Platform for gene editing. It combines elements of the Company’s earlier tools, and allows researchers to design genome editing vectors and cloning strategies optimized to their own laboratories and experimental needs. The DeskGen platform gives life scientists the power to expertly design optimized genome editing experiments in any cell […]

April 25, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 22 Apr 2015

Vaccines against Parasites, on the Horizon with XstalBio

XstalBio has commenced work on an €9.3M EU Funded Horizon 2020 project to develop vaccines that protect cattle, sheep and poultry, against infection by parasites. The 4 year “PARAGONE” collaboration involves 17 partners from Europe, Uruguay and China and will aim to move several candidate vaccines from the laboratory into practical field trials. XstalBio, as […]

April 22, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 18 Apr 2015

Another Partnership between Immunocore and MedImmune against Skin Cancer

Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer and other diseases, and MedImmune, the global biologics research and development arm of AstraZeneca have just entered into a second effective collaboration for a potential skin cancer treatment. It concerns melanoma which is a form of skin cancer that accounts for less than five per cent of […]

April 18, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 16 Apr 2015

The first-in-human Phase I trial for a treatment against glaucoma core

Isarna Therapeutics has initiated Phase I clinical trial with ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta (TGF-ß2) to treat advanced glaucoma. This first-in-human Phase I trial, conducted at the University Hospitals of Mainz and Tuebingen, Germany, is designed to evaluate the safety and long-term tolerability of ISTH0036 in patients with advanced glaucoma […]

April 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Apr 2015

flash4science, the life science private shopping club

Any scientist knows how expensive purchasing new equipment can be. However, one platform, flash4Science, in particular caught our attention. The company located in Germany has set itself an interesting challenge as it tries to combine life sciences and private shopping together. Two domains, which, on paper, seem completely incompatible! It is the world’s first biotech […]

April 16, 2015 - 2 minutesmins - By Alexandre Lowrey

News and Trends 15 Apr 2015

AstraZeneca avoided a public crisis of its marketed diabetes treatment

Last week, FDA expressed its concerns about AstraZeneca’s treatment for type 2 diabetes, Onglyza. According to Reuters, FDA found “significant or near significant” increase of death risk. However, the agency also admits that the cause of death is multifactorial and could not be directly related to AstraZeneca’s treatment. The drug was developed as a result […]

April 15, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

United Kingdom

PhoreMost awarded €1.96M to target the “undruggable” Cancer Genes

Succesful Phase III for Indivior’s Schizophrenia treatment

GSK sparks off the Gene Therapy resurgence

Kymab secures €79.8 Million to develop its Antibody-Generating technology

Natural Killer therapies for Cancer: a Fast-Evolving field

Sygnis on the way to conquer the UK Life Sciences market

Desktop Genetics launches a new Gene Editing Platform

Vaccines against Parasites, on the Horizon with XstalBio

Another Partnership between Immunocore and MedImmune against Skin Cancer

The first-in-human Phase I trial for a treatment against glaucoma core

flash4science, the life science private shopping club

AstraZeneca avoided a public crisis of its marketed diabetes treatment

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!